ASCO-GU 2025: ACCEL trial launch

Dr. Ramy Saleh presents the ACCEL phase Ia/Ib/II clinical trial—investigating the safety, tolerability, efficacy, and dosimetry of Actinium-225-PSMA-62 in men with oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer.